 Connection
Sarah Tevis to Neoadjuvant Therapy
This is a "connection" page, showing publications Sarah Tevis has written about Neoadjuvant Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.367 |
|
|
|
-
Vemuru S, Huang J, Colborn K, Yoon Y, Huynh V, Leonard L, Ahrendt G, Christian N, Afghahi A, McLemore L, Sams S, Tevis S. Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy. Breast Cancer Res Treat. 2023 Jul; 200(2):247-256.
Score: 0.170
-
Huynh V, Yang J, Bronsert M, Ludwigson A, Ahrendt G, Kim S, Matlock DD, Cohen J, Hampanda K, Tevis SE. Choosing Between Mastectomy and Breast-Conserving Therapy: Is Patient Distress an Influencing Factor? Ann Surg Oncol. 2021 Dec; 28(13):8679-8687.
Score: 0.149
-
Flanagan MR, van den Bruele AMB, Downs-Canner SM, Thomas SM, Gallagher KK, Jakub JW, Tevis SEA, Verdial FC, Zhang JQ, Elmore LC, Mukhtar RA, Brennan M, Lillie M, Gibson TC, Verosky A, Plichta JK, Rosenberger LH. A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer. Ann Surg Oncol. 2025 Aug; 32(8):5551-5562.
Score: 0.049
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|